We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The data also “showed that similar percentages of patients improved between the two treatment arms, 57 percent for tradipitant and 50 percent for placebo,” Vanda acknowledged. Read More
Hospitalized COVID-19 patients with pneumonia improved sooner when treated with Vanda Pharmaceuticals’ investigational anti-inflammatory drug tradipitant compared to a placebo, according to interim results from a phase 3 trial. Read More
A second study evaluating the use of the popular heartburn drug famotidine in patients with severe COVID-19 has found that the treatment reduced deaths and the need for intubation. Read More
CanSino Biologics’ experimental COVID-19 vaccine has entered a late-stage trial in Russia, the company leading the study announced yesterday. Read More